Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer

Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC

Becotarug plus osimertinib shows survival benefit in EGFR exon 20 insertion lung cancer

TQB2922 combination shows high response rates in EGFR-mutant lung cancer after tyrosine kinase inhibitor resistance

SHR-A2009 plus EGFR tyrosine kinase inhibitor shows promising activity in EGFR-mutant lung cancer

Sevabertinib shows manageable diarrhoea without impacting efficacy in HER2-mutant lung cancer

Subcutaneous amivantamab plus lazertinib shows durable responses in EGFR-mutant advanced lung cancer

Distinct lung microbiome patterns identified in Portuguese patients with lung cancer

T-cell engagers in lung cancer: Strategies to prevent and manage toxicities

Cracking the code: Bispecific immunotherapy in small cell lung cancer

ATR inhibitor plus durvalumab does not improve survival over docetaxel in advanced NSCLC

Durvalumab after SBRT reduces tumour progression in early-stage NSCLC